Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | ACACB | O00763 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5543202 | 1.00 | DRD2 (0.54) | DRD2SIGMAR1ACACBPKMALDH1A1 | |
| SCHEMBL5549964 | 1.00 | DRD2 (0.54) | DRD2SIGMAR1ACACBPKMALDH1A1 | |
| SCHEMBL5543293 | 0.84 | DRD2 (0.55) | DRD2SIGMAR1ACACBKDM1AMAOB | |
| SCHEMBL5548799 | 0.84 | DRD2 (0.55) | DRD2SIGMAR1ACACBKDM1AMAOB | |
| SCHEMBL26185843 | 0.83 | SIGMAR1 (0.53) | DRD2SIGMAR1ACACB | |
| SCHEMBL29157993 | 0.81 | DRD2 (0.52) | DRD2ALDH1A1KDM1AMAOB | |
| SCHEMBL31114636 | 0.79 | EPHX2 (0.57) | DRD2PKMALDH1A1MAPTKDM1A | |
| SCHEMBL8066651 | 0.79 | DRD2 (0.54) | DRD2ACACBKDM1AMAOB | |
| SCHEMBL2649560 | 0.77 | KDM1A (0.55) | DRD2ACACBALDH1A1KDM1AMAOB | |
| SCHEMBL2649557 | 0.77 | KDM1A (0.55) | DRD2ACACBALDH1A1KDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050192324-A1 | Novel dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof | GLENMARK PHARMACEUTICALS LTD. (IN) | 2005-09-01 | — | — | US | claimed |
| US-7230002-B2 | Dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof | GLENMARK PHARMACEUTICALS LTD. (IN) | 2007-06-12 | — | — | US | disclosed |
| US-20050192324-A1 | Novel dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof | GLENMARK PHARMACEUTICALS LTD. (IN) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192324-A1 | Novel dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof | DPP4, DPP3, DPP7 | DRD2 3398/4885SIGMAR1 4155/4885ACACB 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.